Loading...
Loading...
CNTG| Name | Value |
|---|---|
| Revenues | 10.3M |
| Cost of Revenue | 6.5M |
| Gross Profit | 3.9M |
| Operating Expense | 14.2M |
| Operating I/L | -10.5M |
| Other Income/Expense | 0.1M |
| Interest Income | 0.0M |
| Pretax | -11.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -6.5M |
Centogene N.V. and its subsidiaries specialize in rare diseases, leveraging clinical and genetic data to provide actionable information for patients, physicians, and pharmaceutical companies globally. The company operates in three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. It offers rare disease platform services, including target discovery, patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring, as well as genetic sequencing and diagnostics services. Additionally, it provides COVID-19 testing solutions such as PCR and antigen testing services. Centogene N.V. generates revenue through collaborations, license agreements, and direct provision of services to physicians, laboratories, hospitals, and distributors.
